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Abstract
Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the
most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have
a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current
and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed.
We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is
replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard
arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of
relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally,
we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA
analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood
samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.
Clinical Lung Cancer, Vol. 21, No. 2, e61-4 ª 2019 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Surveillance After Definitive TherapyIntroduction
The 5-year survival rate of Danish lung cancer patients diagnosed
with locoregional disease ranges from 43% for patients with stage I
disease, 27% for stage II disease, and 10% for patients with stage III
disease.1,2 Because of the high risk of relapse, active surveillance
after curative-intent treatment is recommended.3 Unfortunately,
our knowledge of how to do this most efficiently is poor. None-
theless, a standardized surveillance program for patients treated for
lung cancer was introduced in Denmark in 2016.4 For patients with
stage I-III lung cancer, this program includes clinical control and
contrast-enhanced (ce) computed tomography (CT) every 3 months
for the first 2 years after definitive treatment, then every 6 months
from year 3 to 5.
The SUPER Trial: Study Protocol
Objectives
To improve early detection of treatable relapse of lung cancer,
thereby improving patient survival and quality of life (QoL).
Design
The study is an investigator-initiated national multicenter ran-
domized clinical trial designed first to assess if surveillance withFigure 1 Patient Flow
Clinical Lung Cancer March 202018F-fludeoxyglucose positron emission tomography (PET)/ceCT
can increase the number of treatable relapses, and second to
concurrently collect liquid biopsy samples for later analysis, poten-
tially enabling even earlier and minimally invasive detection and
characterization of relapse.
The aim is to include and randomize a total of 750 patients from
all 5 regions of Denmark from the departments of pulmonology and
oncology with stage I-III nonesmall-cell lung cancer (NSCLC)
after treatment with curative intent. These patients are currently,
after their definitive treatment, followed with ceCT (thorax and
upper abdomen) every 3 months for the first 2 years. In the trial,
patients will be randomized 1:1 to the interventional arm (arm A)
with PET/ceCT (vertex to the midfemoral region) replacing ceCT
at months 6, 12, 18, and 24, or to the standard arm (arm B) with
ceCT every 3 months. In both arms, patients will undergo clinical
evaluation, QoL assessment, and liquid biopsy sampling every 3
months. Patients will be stratified by site, sex, and lung cancer stage.
The primary endpoint is number of relapses treatable with
curative intent. Secondary endpoints are as follows: time to verified
relapse, overall survival (OS), OS for patients with relapse, perfor-
mance status at relapse, QoL at relapse, number and type of invasive
procedures to assess whether patients experienced relapse, number
Figure 2 Randomization Arms
Kristin Skougaard et aland type of invasive procedures to assess incidental findings,
including any adverse events due to these invasive procedures, cost-
effectiveness and health care costs, and type of treatment after
verification of relapse.
A study scheme is shown in Figure 1, and the 2 randomization
arms are shown in Figure 2.
Eligibility
Patients are eligible if they are diagnosed with stage I-III lung
cancer treated with curative intent with one or more of the
following modalities: resection, chemotherapy, radiofrequency
ablation, and radiotherapy, with or without adjuvant treatment.
Also, the patients shall have no evidence of recurrent disease on the
control ceCT performed 3 months after definitive treatment.
Follow-up
After 24 months of follow-up, all included patients will continue
in the standard follow-up program for years 3 to 5.
For primary endpoint analysis, patients will be followed until the
first confirmed relapse or for up to 3 years after randomization,
whichever comes first. For survival analysis, patients will be followed
until death or for a minimum of 1 year after the last scan performed
related to this project. Because it may be difficult to discriminate if a
relapse is a true relapse of the lung cancer or a new primary lung
cancer, a relapse will comprise both. If a secondary cancer is diag-
nosed during the project period, patient data will be censored at this
point, unless it is a cancer with a prognosis expected to be signifi-
cantly better than NSCLC, such as small localized tumors in the
breast, thyroid, or colon. All findings that hint at relapse and/or
secondary cancer will, as far as clinically possible, be verified by
biopsy. Diagnosis and treatment of relapse will ultimately be
decided by the local multidisciplinary tumor board.
Biomarker and QoL Analyses
Liquid biopsy samples will be drawn before initiation of therapy
(baseline) and at follow-up visits as close to the scheduled imaging
(ceCT or PET/ceCT) as possible. All samples will be analyzed for
amount of cell-free DNA and for selected tumor markers in
circulating tumor DNA (ctDNA). The dynamics of ctDNA will be
compared to ceCT or PET/ceCT findings. In addition, if feasible,
potential biomarkers related to disease relapse will be assessed.
To examine the participants’ QoL during follow-up and at the
time of relapse, they will be asked to fill in a QoL questionnaire
(European Organization for Research and Treatment of CancerQLQ C-30, LC-13, and GAD-7). The purpose of this is 2-fold:
first, to explore how the intervention and detection of relapse in-
fluences patient-experienced QoL, and second, to enable a cost-
effectiveness analysis that examines the cost per quality-adjusted
life-year (QALY), an outcome measure combining quantity and
QoL after a given intervention.
Statistical Analysis
The protocol started inclusion in the Capital region in October
2018. Two more regions started inclusion in January 2019 and yet
another one in October 2019. The remaining region will soon
follow.
To detect a 15% increase in the proportion of patients with
relapses offered treatment with curative intent (from the currently
estimated 31%2 to 46%) in the PET arm, power calculations
resulted in a sample size of 330 patients, 165 patients per group.
Estimating that 45% of the included patients will experience relapse
within 24 months, a total of 165/0.45 ¼ 367 patients should be
included in each arm (for a total of 734). We aim to include 375
patients in each arm. The Fisher exact test will be used to test for an
increase in the proportion of patients with relapse.
The cost-effectiveness of the 2 arms is assessed with the incre-
mental cost-effectiveness ratio—that is, the ratio of net health care
costs to net QALYs.
Analysis of covariance will be used to assess the difference in
changes in QoL score (symptom burden and functional scales) and
performance status between the 2 arms, adjusting for QoL score at
baseline. Median OS will be estimated via the Kaplan-Meier
method.
Ethics
The study will be performed in accordance with the Declaration
of Helsinki and Danish law. All patients must provide written
informed consent before inclusion in the study, and all data will be
treated with confidentiality. Approval by the Regional Committee
on Health Research Ethics and the Danish Data Protection Agency
was obtained before study initiation (approval H-18009536). Pa-
tient information is protected by the Personal Data and Health Acts
Act. The study is registered at ClinicalTrials.gov (NCT03740126).
Discussion
In recent guidelines, PET/ceCT has replaced ceCT as the pri-
mary staging examination.5 The superiority of PET/CT is primarily
based on an increased sensitivity for mediastinal and distantClinical Lung Cancer March 2020 - e63
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e64 -metastases.6,7 Currently, PET/CT is neither routinely performed
nor recommended during follow-up, except in cases of suspected
relapse in patients who are candidates for salvage therapy or after
inconclusive ceCT.8 Especially after radiotherapy, ceCT is known to
have limited accuracy, which can potentially delay the diagnosis of a
relapse.9 The diagnostic accuracy of PET/ceCT for detection of
relapse has been evaluated in several mainly small and retrospective,
highly heterogeneous studies. These were presented in a compre-
hensive review including 13 studies with 1035 patients in total. This
review emphasizes the superior accuracy of PET/ceCT over ceCT,
mainly because of its improved sensitivity.10
A Swiss single-center randomized study of 93 patients compared
PET/ceCT with ceCT of the chest as surveillance after curatively
treated NSCLC. Scans were performed every 6 months. The study
did not find PET/ceCT to be better than ceCT in detection of
recurrence, however, thus emphasizing that the sample size was too
small to detect minor differences or to discriminate between treat-
ment modality and stage.11 Despite the scarcity of evidence, the use
of PET/ceCT for follow-up has been increasing, but better evidence
for the role of PET/ceCT is needed.12
Blood carries various potential cancer biomarkers, such as
circulating tumor cells, microRNA, and ctDNA. In particular,
ctDNA detected in plasma or serum has been shown to be a
valuable prognostic and predictive marker for early detection of
relapse.13,14 It is now possible to detect ctDNA in patients with low
tumor burden (eg, in early-stage NSCLC or early in the course of
relapse).13,15 To our knowledge, this is the first nationwide initiative
that can potentially deliver biostatistically significant evidence for
implementation of liquid biopsy and ctDNA analysis in standard
patient care.
Conclusion
This trial combining collection of data regarding imaging, QoL,
liquid biopsy, and cost in a multicenter randomized clinical setting
will provide the scientific basis for improving surveillance and
treatment of patients with lung cancer as well as provide knowledge
transferable to other groups of cancer patients.Acknowledgment
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